RESUMEN
OBJECTIVES: To investigate the proliferative activity of the mammary gland epithelium and plasma levels of progesterone, estradiol, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG) in premenopausal women treated with 10 and 20 mg of tamoxifen (TAM) for 22 days. PATIENTS AND METHODS: A randomized double-blind study was performed with 43 premenopausal women with a diagnosis of fibroadenoma of the breast. The patients were divided into three groups: A (n = 15, placebo); B (n = 15, TAM 10 mg/day) and C (n = 13, TAM 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Lumpectomy was performed on the 22nd day of therapy. Normal breast tissue samples were collected during surgery, immediately immersed in 10% buffered formalin, processed for routine histology and immunohistochemistry for proliferating cell nuclear antigen (PCNA) detection. Two peripheral blood samples were collected, both on the 22nd day of the menstrual cycle, in order to evaluate the hormone levels. PCNA expressing epithelial cells were quantified by using a digital program Kontron Image System KS-300 in 1000 cells (400 x ). RESULTS: The percentage of cells expressing PCNA was significantly higher in the group receiving placebo (group A, 50.3%) when compared to groups receiving TAM 10 or 20 mg/day (group B, 24.1%; and group C, 23.2%, respectively) (P < 0.001). Differences between groups B and C were not significant. Levels of progesterone, estradiol and SHBG were significantly higher in B and C groups compared to group A. Increasing concentrations of FSH (P < 0.0045) and lower levels of prolactin (P < 0.0055) were only found in the group receiving 20 mg/day of TAM (group C). CONCLUSIONS: A 22-day TAM therapy, either with 10 or 20 mg/day, significantly reduced the PCNA expression and therefore the proliferative activity of the normal human breast tissue. Increasing levels of estradiol, progesterone and SHBG were associated with TAM therapy at 10 or 20 mg/day. However, a significant change of the level of FSH and prolactin was reached only with a 20-mg/day dose.
Asunto(s)
Antineoplásicos Hormonales/administración & dosificación , Neoplasias de la Mama/prevención & control , Mama/efectos de los fármacos , Fibroadenoma/prevención & control , Tamoxifeno/administración & dosificación , Adolescente , Adulto , Antineoplásicos Hormonales/farmacología , Antineoplásicos Hormonales/uso terapéutico , Mama/citología , Neoplasias de la Mama/sangre , Neoplasias de la Mama/tratamiento farmacológico , División Celular/efectos de los fármacos , Método Doble Ciego , Epitelio/efectos de los fármacos , Femenino , Fibroadenoma/sangre , Fibroadenoma/tratamiento farmacológico , Hormonas Esteroides Gonadales/sangre , Humanos , Premenopausia , Antígeno Nuclear de Célula en Proliferación/metabolismo , Tamoxifeno/farmacología , Tamoxifeno/uso terapéuticoRESUMEN
We report a case of malignant schwannoma of the duodenum, a neural tumor, which rarely occurs in the gastroduodenal tract. The diagnosis was done after an hemorragic episode of the upper gastrointestinal tract and the treatment done was a local resection. Two years later the patient had no symptoms, but the control endoscopy showed a recurrence of the tumor in the second portion of the duodenum and the patient was submitted to a gastroduodenopancreatectomy. The authors reported the case and make a revision on intestinal schwannomas.
Asunto(s)
Neoplasias Duodenales/patología , Neurilemoma/patología , Endoscopía del Sistema Digestivo , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos XAsunto(s)
Antineoplásicos Hormonales/farmacología , Fibroadenoma/tratamiento farmacológico , Fibroadenoma/metabolismo , Antígeno Nuclear de Célula en Proliferación/metabolismo , Tamoxifeno/farmacología , Femenino , Fibroadenoma/patología , Humanos , Inmunohistoquímica , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
The authors present the results of treatment of 10 patients with Ollier's disease using the Ilizarov technique. The Ilizarov device was used to treat leg length discrepancy and to enhance the conversion of chondroma cartilage into normal mature bone, with no curettage and bone grafting. The mean duration of treatment was 9.4 months. This technique was highly efficient in treating the disease. It led to conversion of the abnormal cartilage into histologically mature bone in all patients. Some complications were seen, such as decreased knee mobility, which required prolonged use of the device. The Ilizarov technique is successful in treating patients with Ollier's disease despite some complications and the difficulty in using the technique.
Asunto(s)
Encondromatosis/cirugía , Fijadores Externos , Técnica de Ilizarov/instrumentación , Adulto , Cartílago/fisiopatología , Niño , Condroma/fisiopatología , Condroma/cirugía , Encondromatosis/complicaciones , Fijadores Externos/efectos adversos , Femenino , Fémur/cirugía , Estudios de Seguimiento , Humanos , Artropatías/etiología , Articulación de la Rodilla/fisiopatología , Diferencia de Longitud de las Piernas/cirugía , Masculino , Osteogénesis/fisiología , Rango del Movimiento Articular/fisiología , Tibia/cirugíaRESUMEN
For almost three decades, tamoxifen has been used in the adjuvant treatment of breast cancer. It has also proven effective in the chemoprophylaxis of this disease and in the treatment of cyclic mastalgia. Since a fibroadenoma is a benign hormone-dependent neoplasm which contains estrogen receptor (ER) levels higher than in the mammary lobule, an evaluation of the effect of this drug on the proliferative activity of both the epithelium and the stroma of fibroadenomas in premenopausal women following the administration of 10 or 20 mg/day over 22 days was proposed. Forty women with fibroadenoma were selected for a randomized double-blind trial. They had regular menstrual cycles and had received neither hormones nor become pregnant 12 months prior to this study. Patients were divided into three groups: A (n = 14; placebo), B (n = 13; tamoxifen 10 mg/day), and C (n = 13; tamoxifen 20 mg/day). The treatment was initiated on the first day of their menstrual cycle and the surgeries were performed on the 22nd day. Estradiol, progesterone, and steroid hormone binding globulin (SHBG) were measured twice. The first measurement was performed on the 22nd day of the previous menstrual cycle and the second one was performed on the day of surgery. The fibroadenoma was fixed in 10% formaldehyde solution and stained with hematoxylin and eosin and then processed through immunohistochemical reaction (PC-10, DAKO code number M879, Denmark A/S). The immunoexpression of the proliferative cell nuclear antigen (PCNA) of at least 500 epithelial and 500 stromal cells was evaluated. Such cells were interactively counted using the Kontron Imaging System KS-300 computerized analysis system, with x 400 magnification. As to PCNA expression in the fibroadenomas' epithelium, the average percentage of stained nuclei in groups A, B, and C was 25.2, 19.3, and 18.0, respectively. However, no significant difference was found in the variance analysis of these data (p = 0.168). As to the study of the fibroadenomas' stroma, the average percentage of stained nuclei found in groups A, B, and C was 32.4, 23.2, and 18.4, respectively. The variance analysis (p = 0.031) and Fisher's multiple comparison test (1.39; 26.67 confidence interval [CI]) confirmed that the number of PCNA-expressing nuclei in the stroma was significantly lower in group C (20 mg/day) compared to group A (control). However, there was no significant difference between group B (10 mg/day) and group C (20 mg/day). It was found that tamoxifen reduced the expression of PCNA in the epithelium and the stroma of the fibroadenoma. However, the effect was only statistically significant in the stroma when a 20 mg/day dose was administered.
Asunto(s)
Neoplasias de la Mama/metabolismo , Antagonistas de Estrógenos/farmacología , Fibroadenoma/metabolismo , Neoplasias Hormono-Dependientes/metabolismo , Antígeno Nuclear de Célula en Proliferación/metabolismo , Tamoxifeno/farmacología , Adolescente , Adulto , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Método Doble Ciego , Esquema de Medicación , Epitelio/efectos de los fármacos , Epitelio/metabolismo , Estradiol/sangre , Antagonistas de Estrógenos/administración & dosificación , Femenino , Fibroadenoma/tratamiento farmacológico , Fibroadenoma/cirugía , Humanos , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/cirugía , Premenopausia , Progesterona/sangre , Antígeno Nuclear de Célula en Proliferación/efectos de los fármacos , Globulina de Unión a Hormona Sexual/metabolismo , Células del Estroma/efectos de los fármacos , Células del Estroma/metabolismo , Tamoxifeno/administración & dosificación , Resultado del TratamientoRESUMEN
The purpose of this study was to study the monoclonal antibody MIB-1 in the normal breast epithelium adjacent to a fibroadenoma in women in the luteal phase of the menstrual cycle who were treated with tamoxifen at doses of 10 and 20 mg for 22 days. The proliferative activity of the mammary epithelium adjacent to the fibroadenoma was studied by immunohistochemistry on the basis of the monoclonal antibody MIB-1 (Immunotech, catalog No. 0505, lot 001). The study was randomized and double blind and was conducted on 44 women with fibroadenomas divided into three groups: A (n=16, placebo), B (n=15, tamoxifen, 10 mg), and C (n=13, tamoxifen, 20 mg). Tamoxifen was administered for 22 days starting on the 2nd day of the menstrual cycle, and a biopsy was taken on the 23rd day. Serum estradiol, progesterone, sex hormone binding globulin, follicle-stimulating hormone, luteinizing hormone, and prolactin were measured before treatment (21st and 24th day of the previous menstrual cycle) and on the day of the biopsy. The mean percentage of stained nuclei per 1,000 cells was 9.2 in group A, 4.5 in group B, and 3.2 in group C. The Fisher's test revealed that tamoxifen significantly reduced MIB-1 at doses of 10 and 20 mg compared with the placebo group (p < 0.0001), with no significant differences between doses in terms of proliferative activity (p=0.21). Groups B and C presented a significant increase in progesterone (p=0.038), estradiol (p < 0.001), and sex hormone binding globulin (p=0.001) levels. Elevation of serum follicle-stimulating hormone concentration (p=0.0045) and a fall in prolactin levels (p=0.0055) were observed. We conclude that tamoxifen significantly reduced the proliferative activity of the mammary epithelium at the doses of 10 and 20 mg/day.
Asunto(s)
Anticuerpos Monoclonales , Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Mama/patología , Fibroadenoma/tratamiento farmacológico , Proteínas Nucleares/inmunología , Tamoxifeno/uso terapéutico , Adolescente , Adulto , Antígenos Nucleares , Antineoplásicos Hormonales/administración & dosificación , Antineoplásicos Hormonales/farmacología , Mama/efectos de los fármacos , Mama/inmunología , Neoplasias de la Mama/patología , División Celular , Método Doble Ciego , Epitelio/efectos de los fármacos , Epitelio/inmunología , Epitelio/patología , Femenino , Fibroadenoma/patología , Humanos , Inmunohistoquímica , Antígeno Ki-67/inmunología , Fase Luteínica , Premenopausia , Tamoxifeno/administración & dosificación , Tamoxifeno/farmacologíaRESUMEN
We describe two patients who underwent cardiac transplantation for chronic cardiomyopathy of Chagas' disease, and in whom the disease was reactivated with the development of cutaneous lesions. In both cases, the skin lesions regressed completely after 2 months of therapy with allopurinol.
Asunto(s)
Alopurinol/uso terapéutico , Antiparasitarios , Enfermedad de Chagas/tratamiento farmacológico , Trasplante de Corazón , Tripanocidas/uso terapéutico , Adulto , Cardiomiopatía Chagásica/cirugía , Enfermedad de Chagas/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Enfermedades Cutáneas Parasitarias/patologíaRESUMEN
Fourteen boys (56%) and 11 girls (44%) 4 to 17 years of age (mean, 12.2 years) who had osteosarcoma and open epiphyseal plates were studied. A possible correlation between transepiphyseal spread of osteosarcoma and radiologic and histopathologic findings was investigated. Epiphyseal plate invasion was detected radiologically in only 11 patients (44%), whereas histopathologic examination showed transepiphyseal extension in 21 patients (84%). The authors conclude that the epiphyseal plate is not a barrier against tumor growth and strongly recommend that limb salvage surgery preserving the epiphysis be planned carefully.
Asunto(s)
Neoplasias Óseas/patología , Placa de Crecimiento/patología , Osteosarcoma/patología , Adolescente , Neoplasias Óseas/cirugía , Niño , Preescolar , Femenino , Placa de Crecimiento/cirugía , Humanos , Masculino , Invasividad Neoplásica , Osteosarcoma/cirugía , PronósticoRESUMEN
Neuroblastoma is the second most common solid tumor occurring in children. Amplification of the MYCN oncogene is associated with poor prognosis. To identify neuroblastoma tumors with MYCN amplification, we studied the number of copies of MYCN in interphase cells by fluorescence in situ hybridization in 20 neuroblastoma patients. MYCN amplification appeared in 7 tumor specimens. Interphase and metaphase studies showed a tumor cell population with both forms of amplification, double minutes and homogeneously staining regions, in two patients. These patients showed a smaller tumor cell subpopulation with the presence of more than one homogeneously staining region, suggesting that gene amplification was undergoing karyotype evolution.